Related Experiment Videos

Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model

D Robert Siemens1, Scott Crist, J Christopher Austin

  • 1Department of Urology, Cancer Center and Prostate Cancer Research Group, University of Iowa, Iowa City, IA, USA. siemensr@kgh.kari.net

The Journal of Urology
|August 13, 2003
PubMed
Abstract

Insights

For bladder cancer gene therapy, attenuated vaccinia virus (NYVAC) and canarypox virus (ALVAC) show superior gene transfer efficiency compared to adenovirus vectors in preclinical models.

Area of Science:

  • Oncology
  • Gene Therapy
  • Virology

Background:

  • Gene transfer efficiency and cell targeting are critical challenges in preclinical gene therapy for malignant diseases.
  • Previous intravesical gene transfer attempts in bladder cancer models yielded inconsistent urothelial and tumor transgene expression.

Purpose of the Study:

  • To compare the gene transfer efficiencies of different viral vectors in bladder cancer models.
  • To evaluate replication-deficient adenovirus, attenuated vaccinia virus (NYVAC), and canarypox virus (ALVAC) for gene therapy applications.

Main Methods:

  • In vitro and orthotopic murine bladder cancer models were used to assess gene transfer efficiency.
  • Replication-deficient adenovirus, NYVAC, and ALVAC vectors were compared using beta-galactosidase and firefly luciferase reporter genes.

Main Results:

  • NYVAC and ALVAC demonstrated significantly higher in vitro transgene expression compared to adenovirus vectors.
  • Adenovirus vectors showed inferior gene transfer efficiency into bladder urothelium and orthotopic tumors versus ALVAC and NYVAC.
  • Bladder tumor cells lacked the coxsackie-adenovirus receptor, while normal bladder tissue expressed it highly, explaining adenovirus's poor gene transfer.

Conclusions:

  • Significant differences in gene transfer were observed among the tested viral vectors in an orthotopic bladder cancer model.
  • Vector selection is crucial for optimizing gene therapy protocols in bladder cancer treatment.

Related Concept Videos